anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The effectiveness of sertraline hydrochloride in the treatment of social anxiety disorder (also known as social phobia) was established in two multicenter placebo-controlled studies (Study 1 and 2) of adult outpatients who met DSM-IV criteria for social anxiety disorder.

Study 1 was a 12-week, multicenter, flexible dose study comparing sertraline hydrochloride (50–200 mg/day) to placebo, in which sertraline hydrochloride was initiated at 25 mg/day for the first week. Study outcome was assessed by (a) the Liebowitz Social Anxiety Scale (LSAS), a 24-item clinician administered instrument that measures fear, anxiety and avoidance of social and performance situations, and by (b) the proportion of responders as defined by the Clinical Global Impression of Improvement (CGI-I) criterion of CGI-I ≤ 2 (very much or much improved). Sertraline hydrochloride was statistically significantly more effective than placebo as measured by the LSAS and the percentage of responders.

Study 2 was a 20-week, multicenter, flexible dose study that compared sertraline hydrochloride (50–200 mg/day) to placebo. Study outcome was assessed by the (a) Duke Brief Social Phobia Scale (BSPS), a multi-item clinician-rated instrument that measures fear, avoidance and physiologic response to social or performance situations, (b) the Marks Fear Questionnaire Social Phobia Subscale (FQ-SPS), a 5-item patient-rated instrument that measures change in the severity of phobic avoidance and distress, and (c) the CGI-I responder criterion of ≤ 2. Sertraline hydrochloride was shown to be statistically significantly more effective than placebo as measured by the BSPS total score and fear, avoidance and physiologic factor scores, as well as the FQ-SPS total score, and to have significantly more responders than placebo as defined by the CGI-I.

Subgroup analyses did not suggest differences in treatment outcome on the basis of gender. There was insufficient information to determine the effect of race or age on outcome. 

In a longer-term study, patients meeting DSM-IV criteria for social anxiety disorder who had responded while assigned to sertraline hydrochloride (CGI-I of 1 or 2) during a 20-week placebo-controlled trial on sertraline hydrochloride 50–200 mg/day were randomized to continuation of sertraline hydrochloride or to substitution of placebo for up to 24 weeks of observation for relapse. Relapse was defined as ≥ 2 point increase in the Clinical Global Impression – Severity of Illness (CGI-S) score compared to baseline or study discontinuation due to lack of efficacy. Patients receiving sertraline hydrochloride continuation treatment experienced a statistically significantly lower relapse rate over this 24-week study than patients randomized to placebo substitution.
Early range of motion and delayed weight bearing (ROM). The range of motion group was restricted completely from weight-bearing until week 6, allowed partial weight-bearing after 6 weeks and full weight-bearing after 8 weeks. In addition to this, the patients were instructed to perform tendon strain exercises, five times a day, from week 2. The exercises were performed by removing the foot from the brace and then perform light dorsal ankle movement, 25 repetitions/time, when sitting on a table.
Use of propofol injectable emulsion infusions for both adult and pediatric ICU sedation has been associated with a constellation of metabolic derangements and organ system failures, referred to as Propofol Infusion Syndrome, that have resulted in death. The syndrome is characterized by severe metabolic acidosis, hyperkalemia, lipemia, rhabdomyolysis, hepatomegaly, renal failure, ECG changes (Coved ST segment elevation -similar to ECG changes of the Brugada syndrome) and/or cardiac failure. 

The following appear to be major risk factors for the development of these events: decreased oxygen delivery to tissues; serious neurological injury and/or sepsis; high dosages of one or more of the following pharmacological agents: vasoconstrictors, steroids, inotropes and/or prolonged, high-dose infusions of propofol (> 5 mg/kg/hour for > 48 hours). The syndrome has also been reported following large-dose, short-term infusions during surgical anesthesia. In the setting of prolonged need for sedation, increasing propofol dose requirements to maintain a constant level of sedation, or onset of metabolic acidosis during administration of a propofol infusion, consideration should be given to using alternative means of sedation. 

Prescribers should be alert to these events in patients with the above risk factors and immediately discontinue propofol when the above signs develop.
TRUDHESA is for nasal administration only and must not be injected.

TRUDHESA must be assembled prior to use (see Instructions for Use). Use or discard TRUDHESA within 8 hours once the vial has been opened or the product has been assembled.

Prime the assembled TRUDHESA before initial use by releasing 4 sprays. Use TRUDHESA immediately after priming. Discard TRUDHESA immediately after use. Open and prepare a new TRUDHESA if an additional dose is needed.
Drug-loaded microbead compositions including a plurality of individual microbeads of a biodegradable material, a plurality of individual vesicular agents, a first therapeutic agent, and a second therapeutic agent different from the first therapeutic agent. The vesicular agents include at least one lipid bilayer surrounding a vesicular core. The first therapeutic agent is associated with the individual vesicular agents. For example, the first therapeutic agent may be contained within the individual vesicular agents or may be associated with the individual vesicular agents by ionic or non-covalent interaction. The second therapeutic agent is different from the first therapeutic agent and contained within the individual microbeads or associated with the individual microbeads through ionic or non-covalent interaction. The second therapeutic agent may or may not be associated with the individual vesicular agents. Drug-loaded biodegradable microbead compositions include microbeads of biodegradable material and a therapeutic agent associated with N the microbeads.
The invention relates to the technical field of biological medicine, in particular to a siRNA delivery biomimetic liposome and a preparation method thereof, which can be used for specifically delivering siRNA to pancreatic cancer cells. By camouflage of cancer cell membranes, the liposome can evade uptake by the mononuclear megaphagy system, actively target the tumor site and be preferentially taken up by homologous tumor cells. The bionic liposome can inhibit autophagy of pancreatic cancer cells, up-regulate megaloblastic, and enable cells to take in more albumin-bound taxol (nanoparticle albumin-boundpaclitaxel, nab-PTX). In a pancreatic cancer mouse model, the bionic membrane fusion liposome and Nab-PTX combined treatment has better curative effects than double-dose Nab-PTX monotherapy groups in the aspects of slowing down tumor growth, prolonging the service life of tumor-bearing animals and relieving tumor metastasis. And, the combination therapy does not cause immune, systemic, blood and organ toxicity, with good biosafety, compared to the apparent toxicity of high doses of Nab-PTX. The bionic liposome provided by the invention provides a novel alternative combined chemotherapy scheme for pancreatic cancer.
The invention discloses a traditional Chinese medicine combination for treating enuresis and frequent micturition. The traditional Chinese medicine combination is mainly prepared from, by weight, 10-40 parts of black ants, 2-6 parts of radix glycyrrhizae and 2-6 parts of pericarpium citri reticulatae. According to the traditional Chinese medicine combination for treating enuresis and frequent micturition, three kinds of natural traditional Chinese medicines are selected to be scientifically combined, a prescription is simple, and the traditional Chinese medicine combination is set for enuresis and frequent micturition caused by deficiency of vital energy of spleen and kidney. Child or adult enuresis and frequent micturition are related to the deficiency of vital energy of the spleen, the kidney and the lung, especially to the deficiency of vital energy of the spleen and the kidney. In the prescription, the black ants serve as a monarch medicine and have the effects of tonifying the kidney and the spleen, benefiting qi and supporting the healthy energy; the radix glycyrrhizae and the pericarpium citri reticulatae are adjuvant and have the effects of benefiting qi and tonifying the spleen and can reconcile the materials. The traditional Chinese medicine combination becomes effective quickly, treats both symptoms and root causes and has no toxic or side effect, and a preparation method for the traditional Chinese medicine combination is simple, and the traditional Chinese medicine combination is convenient to take and low in cost.
Culturally Targeted Narrative Video: "Is My Cancer Hereditary? Rosa Visits a Genetic Counselor." Participants in the video arm will be asked to watch an 18-minute video that the research team developed and tested previously about HBOC and genetic services. The video is recorded with Spanish audio and is available with English subtitles.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, and aims at treating chronic bowel diseases. In the morning, ozone therapy is applied. Overnight, hydrogel containing sodium alginate with Dimexidum in the concentration 6-9 % is introduced through rectum. The medicinal agent is introduced in amount 50-100 ml, with exposition of 4-6 hours. Therapy course is 5-7 daily sessions. ^ EFFECT: method allows relieving inflammatory process and reducing length of treatment. ^ 3 ex
Bipolar (BP) disorder is a chronic illness of profound shifts in mood ranging from mania to depression. BP is successfully treated by combining medication with psychosocial therapy, but care can prove inadequate in practice. With gaps in coverage and medication, along with imprecise guidelines on when, where, and how to intervene, promising psychosocial therapies require adaptive strategies to better address the specific needs of individuals in a timely manner. However, To accomplish this, evidence based practices are needed. This project aims to address this knowledge gap by establishing a mobile health platform for translating a psychosocial therapy in BP into an effective adaptive intervention.

The research to be conducted under this protocol falls under the general heading of a micro-randomized trial. It investigates feasibility of a study on how to tailor an intervention based on acceptance and commitment therapy (ACT) when delivered via a smartphone app. Long-term objective of this study is to develop a mobile health platform for the translation of a psychosocial intervention for bipolar disorder (BP) into an effective adaptive intervention. In this particular part of the study, the investigator will assess the feasibility of a mobile health and wearable device platform for the translation of a BP psychosocial therapy into an evidenced-based adaptive intervention. To answer this question, investigator will study how individuals with BP respond to a microintervention delivered via a mobile app. Primary outcome of this study is to evaluate the feasibility of a micro-randomized trial in ACT in terms of completion of assessments (interview and self-report), wearing of Fitbit, and completion of microintervention questions. Secondary outcome of the study is to detect a linear effect in time of the microintervention on symptom levels of mania and depression in individuals with bipolar disorder. The estimated linear effect would be used to power a larger study.Enrollment is by invitation only; participants in the study will be recruited from the Prechter Longitudinal Study of Bipolar Disorder (HUM606).
Gonadotrophins IM daily (HMG 75 IU, Merional, IBSA)was administrated from day 2 of the cycle. Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration. The GnRH antagonist (Cetrotide) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC.
A formulation for parenteral administration is described which includes: iodised oil, a selenium source such as barium selenate particles and a thickening agent such as beeswax. The formulation components ensure that the selenium source remains substantially suspended within an iodised oil mixture before and after administration. The formulation on administration forms a depot and slowly releases iodine and selenium over an extended time period of at least 90 days. The formulation has the advantage of providing a single dose product for delivery of both iodine and selenium elements to an animal such as a sheep and, has also been found to pass to progeny when administered to a ewe during gestation. Associated methods and uses are also described for administering the formulation and to manufacture the formulation. Further methods are also described to measure iodine levels and from the results determine whether or not iodine supplementation is required.
PURPOSE: To obtain a powder excellent in both water and oil repellency, causing no messy makeup, and good in use feeling, by treating powder with a solution prepared by dissolving a specific (meth)acrylate homopolymer or copolymer in an organic solvent. CONSTITUTION: This powder is obtained by treating powder with a polymer composed of recurring unit derived from a polyfluoroalkyl-contg. (meth)acrylate of formula I (Rf is a polyfluoroalkyl; A is an alkylene, etc.; X is H or methyl), or with a copolymer composed of the above recurring unit, recurring unit derived from an alkyl (meth)acrylate of formula II ((n) is 12-22) and/or recurring unit derived from a silicone macromonomer of formula III ((n) is 5-200). This powder is inexpensive, being simple is production process. The amount of the above homopolymer or copolymer to be used is 1-10 pts.wt. based on 100 pts.wt. of the original powder which is e.g. talc, kaolin, mica, titanium dioxide.
Cohort 4, AD patients, will receive an ICG infusion of 2 mg/min for 120 minutes. The first 5 subjects will serve as a satellite group. If no adverse effects are observed, then a further 10 AD patients will receive a 2 mg/min ICG infusion (n = 15 total for Cohort 4). Recruitment of AD patients will begin if there are no dose limiting adverse effects observed in the satellite group of healthy elderly.
Older 65 people who live alone in their house will be included. They will have Individual interviews.
Compositions and methods are provided for inducing death of cancer cells through apotposis mediated by the death ligand, TRAIL. The method comprising: introducing an expression vector into a group of cells comprising cells that express a receptor for TRAIL. The expression vector comprises a polynucleotide sequence encoding TRAIL whose expression is preferably regulated by a conditional promoter in the vector. The cells into which the expression vector is introduced express TRAIL when conditions are suitable to activate the conditional promoter. The expressed TRAIL induces cell death in those cells which express the TRAIL receptor through interaction between TRAIL and the receptor such as DR4 and DR5. The method can be used for treating tumors site-specifically and in a dose-adjustable manner.
Root canal shaping will be completed with a heat-treated nickel titanium OneCurve Mini #25/0.4 rotary file (Micro-Mega, Besancon, France) after reaching the apical region with #10 K stainless steel files (Dentsply Maillefer, Ballaigues, Switzerland). The irrigation solution will be used by adapting an ultrasonic tip (IRRI S 21/25; VDW, Munich, Germany) to an ultrasonic device (VDW Ultra; VDW, Munich, Germany). The tip will be activated a total of three times, each cycle lasting 20 s and involving the use of 1 ml of 3% NaOCl. Then 2 ml of 17% EDTA solution will be activated for 1 minute as described above. The ultrasonic tip will be placed 2 mm shorter than the working length without touching the canal walls.
Cyclic nucleotide phosphodiesterases (PDEs) consist of a family of enzymes expressed in several types of cells, including inflammatory cells, that play a pivotal role in inflammation. Several studies have demonstrated that the inhibition of PDE4 results in a reduced inflammatory response via PKA and CREB signaling. Hence, PDE4 suppression improves the inflammatory feedback typical of several diseases, such as inflammatory bowel disease (IBD). In our previous studies, we have demonstrated that miR-369-3p regulates inflammatory responses, modulating different aspects of the inflammatory process. The aim of this study was to demonstrate an additional anti-inflammatory effect of miR-369-3p targeting PDE4B, one of the widely expressed isoforms in immune cells. We found that miR-369-3p was able to reduce the expression of PDE4B, elevating the intracellular levels of cAMP. This accumulation increased the expression of PKA and pCREB, mitigating the release of pro-inflammatory cytokines and promoting the release of anti-inflammatory cytokines. To prove that PDE4B is a good therapeutic target in IBD, we also demonstrate that the expression of PDE4B was increased in UC patients compared to healthy controls, affecting the immune infiltrate. PDE4B is considered an important player in inflammatory progression; hence, our results show the ability of miR-369-3p to ameliorate inflammation by targeting PDE4B, supporting its future application as a new therapeutic approach in IBD.
Compounds (except N1-cyclopropyl-5-((2-(((2-chloroethylamino)carbonyl)amino)-4-pyridyl)oxy)-1H-1-indolecarboximide) represented by general formula (I), and pharmaceutical compositions comprising compounds represented by general formula (I), are disclosed. These compounds are useful as angiogenesis inhibitors. The use of a compound of general formula (I) for the manufacture of an antitumor agent is also described. The tumor may be pancreatic cancer, a gastric cancer, a colon cancer, a breast cancer, a prostate cancer, a lung cancer, a renal cancer, a brain tumor, a blood cancer or an ovarian cancer. The use of a compound of general formula (I), a salt thereof, or a hydrate of the foregoing for the manufacture of: a therapeutic agent for hemangioma a cancer metastasis inhibitor a therapeutic agent for retinal neovascularization or diabetic retinopathy a therapeutic agent for atherosclerosis of a prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective, or a therapeutic agent for an inflammatory disease, is described. The inflammatory disease may be deformant arthritis, rheumatoid arthritis, psoriasis or delayed hypersensitivity reaction.
This study will explore treating participants who are 18 to 75 years old with Post-Treatment Lyme Disease. IV Ceftriaxone will be delivered in a pulse dose fashion, approximately every 5 days for a total of 9 IV infusions over 6 weeks. Participants will return one month following last treatment, at approximately 3 and 6 months from study start. At each study visit, participants will be asked a number of questionnaires including the SAFTEE assessment to assess the side effects of the drug as compared to placebo; the Fatigue Severity Scale, SF-36, GSQ-30, and PROMIS-29 questionnaires to assess physical functioning, general health, vitality, social functioning, bodily pain, role physical, role emotional, mental health, symptoms, fatigue, anxiety, depression, and sleep disturbances; the CSSRS to assess suicidal ideation.

At the 6-month mark, the study will be unblinded and participants in the placebo group will be invited to repeat the study visits receiving Ceftriaxone. Participants who originally received Ceftriaxone will receive a phone call follow up at 1 year. The duration for both groups is one year. Samples will be collected for safety labs and research assessments.
PURPOSE: To obtain the subject tablet exhibiting an antihypertensive property and capable of maintaining a uniform and constant concentration in blood after oral galenical form absorption by using cellulose or a polymer derived from polyvidone to impart a sustained release property to indapamide. CONSTITUTION: The sustained release of indapamide is adjusted with cellulose or a polymer derived from polyvidone. The polymer derived from the cellulose is used in an amount of about 30-50% based on the whole weight of the tablet and in an amount of about 2-10% based on the polymer derived from the polyvidone. The sustained release of the indapamide is linearly carried out for about 8hr. 50% of the whole amount of the indapamide can especially be released for 5-14hr by changing the percentage of the polymer. When the percentage of the polymer is suitably changed, the indapamide can gradually be released in such an extent that the concentration in human blood reaches 20-80mg/ml at about 24hr after the administration of the oral tablet.
FIELD: cosmetics industry. SUBSTANCE: method provides for preliminary treatment of skin by cleansing masks or by water stream or by vapor containing water extracts of biologically active substances of vegetative origin, with subsequent drying of skin and application to it of cosmetic cream-mask or nourishing cream. Drying of skin is performed by subjecting it during 3-5 min to stream of dry air at speed of 10-40 m/s. Residual moisture content is not over 20% and temperature of 30-70 C, or it can be made by applying to face skin of napkin made of several layers of hygroscopic material. Located between these layers are layers of preliminarily dehydrated particles of sorbent. Average size of particles is equal to 1-50 mcm. Thickness of layers with sorbent particles is 0.5-2 mm. Application of aforesaid method ensures higher efficiency of cream-mask or nourishing cream due to higher absorbility and penetration of its components into deeper layers of skin. EFFECT: higher efficiency. 1 cl, 3 dwg, 3 ex